Celldex (CLDX) Announces Glembatumumab Vedotin Phase 2 Met Primary Objective in c/r Metastatic Melanoma
Go back to Celldex (CLDX) Announces Glembatumumab Vedotin Phase 2 Met Primary Objective in c/r Metastatic Melanoma| CELLDEX THERAPEUTICS, Inc. (NASDAQ: CLDX) | Delayed: 36.26 -0.76 (2.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $37.02 | 52 Week High | $18.62 | |||
| Open | $36.29 | 52 Week Low | $2.85 | |||
| Day High | $37.16 | P/E | N/A | |||
| Day Low | $35.86 | EPS | $-1.02 | |||
| Volume | 1,021,746 | |||||
